Please see enclosed annexure

October 29, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences Please find enclosed the Press Release on the Unaudited Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences. The Press Release is also being uploaded on the website of the Company i.e., www.lauruslabs.com. This is for your information and records. Thanking you. Yours sincerely, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A/a Press Release FOR IMMEDIATE RELEASE 29 OCTOBER, 2026 Laurus Labs Announces H1 FY27 Results Revenues at ₹ 4,233 Cr; EBITDA at ₹ 1,406 Cr, 33.2% margins Hyderabad, October 29, 2026: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company in India announces its Q2 & H1 FY27 results. Financial Summary [₹ Crore] except EPS 2Q FY27 2Q FY26 Y-o-Y 1H FY27 1H FY26 Y-o-Y amounts Revenue 2,206 1,653 33% 4,233 3,223 31% Gross Margins 63.0% 59.9% +3.1% 62.9% 59.6% +3.3% EBITDA 762 429 +78% 1,406 818 +72% EBITDA Margins 34.5% 26.0% +8.5% 33.2% 25.4% +7.8% PBT 592 270 +119% 1,073 494 +117% Net Profit 441 195 +126% 809 358 +126% EPS (Diluted) 8.2 3.6 +128% 15.0 6.6 +127% Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented; “Laurus achieved another record quarter of strong growth in Revenue and Profits, demonstrating the strength of our CDMO platform and Affordable Medicines portfolio as we execute on our transformation strategy. The company operationalized its first commercial scale peptide plant in Vizag utilizing cutting edge operating systems and a significant capacity expansion is already under progress to address surging demand for peptide therapeutics. We also made targeted investments in Oligonucleotides and peptide-resins technologies elevating our integrated CDMO offering. Together this progress reflects our continued commitment on enhancing core capabilities, expanding capacities to deliver greater value for customers and stakeholders.” Corporate Office Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India T +91 40 6659 4333, 2342 0500/501 F +91 40 6659 4320 Registered Office Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com V V Ravi Kumar, Executive Director & Chief Financial Officer commented; “We continue to report strong operational execution for the quarter and made important progress in building strong foundation. Driven by sustained momentum across both CDMO and Affordable Medicine division We have achieved revenue of ₹ 2,206 Cr, representing 33% growth and EBITDA of ₹ 762 Cr, representing 78% growth. The EBITDA margins were strong at 34.5%, supported by improvement in capacity efficiency from growing commercial supplies. Gross margins improved by over 3% pts to 63% due to favorable segment mix. During H1, we achieved ₹ 4,233 Cr in revenue, representing 31% growth and EBITDA of ₹ 1,406 Cr, representing 72% growth, resulting in 33.2% EBITDA margins expanding over 7.8% pts partly supported by Gross margin expansion. We advanced key CAPEX milestone across diversified growth projects and Our capital allocation strategy remains focused on prioritizing investments that support near and long-term growth.” Divisional Revenue Performance [₹ Crore] 2Q FY27 2Q FY26 Y-o-Y 1H FY27 1H FY26 Y-o-Y CDMO 904 518 75% 1,774 1,040 71% Small molecules 875 471 86% 1,710 964 77% Bio 29 47 -38% 64 76 -16% Affordable Medicines 1,302 1,135 15% 2,459 2,183 13% API 625 617 1% 1,280 1,254 2% FDF 677 518 31% 1,179 929 27% Total Revenue 2,206 1,653 33% 4,233 3,223 31% ARV Revenue* 735 733 0.3% 1,404 1,380 2% * Includes API and Formulation (FDF) combined revenue Summary Highlights:  Strong H1 performance; ₹ 4,233 Cr Revenue and 31% revenue growth  Sustained strong growth in CDMO revenue driven by commercial supplies and steady momentum in Affordable Medicines division  ₹ 1,406 Cr EBITDA with a margin of 33.2%, increased by 7.8% pts, contributed by higher CDMO revenue and improving operational leverage. Gross margins expanded by over 3.3% pts to 62.9%  Q2 Revenue ₹ 2,206 Cr; +33% revenue growth, ₹ 762 Cr EBITDA; +78% growth resulted in a margin of 34.5%, Gross margins were at 63%  Announced investments in two technology platforms to strengthen Integrated CDMO offering; Oligonucleotides and peptide-resins  CAPEX % to Revenue reached 20%, reflecting sustained investment in expanding the manufacturing network and niche capabilities  Declared Interim Dividend of ₹ 1.00/- per share Divisional Highlights: CDMO – Small molecules  CDMO business reported revenue of ₹ 1,710 Cr, during H1FY27; increased by 77%  Q2 Revenue of ₹ 875 Cr; increased by 86% Y/Y, driven by advancing late-stage clinical projects, commercial API supplies and ramp-up of new assets  Sustained strong demand in complex/integrated small molecule offerings  Inaugurated Peptide manufacturing facility in Vizag with total Solid Phase Peptide Synthesis (SPPS) capacity >16,000L and we are further expanding capacities to meet growing needs from various partners.  Multiple large-scale API capacity construction in Vizag making good progress  CDMO Pipeline continue to expand on high quality molecules and active projects spread across multiple technologies and by indications BIO – Large molecules  Bio business reported revenue of ₹ 64 Cr, during H1FY27; decreased by 16%  Q2 Revenue of ₹ 29 Cr; decreased by 38% Y/Y due to campaign phasing  Scaling enzymatic technology application across clinical and commercial API projects as part of integrated offerings  LB-4 Fermentation manufacturing unit progressing as planned (>400kL) and set to be commissioned by 3QFY27; actively securing customer capacity commitments. Affordable Medicines  Affordable Medicines division reported revenue of ₹ 2,459 Cr, during H1FY27, increased by 13%  Q2 Revenue of ₹ 1,302 Cr; increased by 15% Y/Y, primarily driven by continued order uptick, consistent volume and pricing resilience across broader ARV and US portfolio  Capacity expansion and resource allocation going as per plan with focus on integrated CMO supplies  KRKA JV updates: Finished formulation site progress on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability  Product filings update: - DMF filings: Cumulatively, 92 DMFs filed till date - Developed market FDF filings: 2 product dossiers filed and a total of 2 approvals received (including Tentative approvals) in H1. Cumulatively, 96 products filed till date R&D and Other Highlights:  Total R&D investments including capex R&D for H1FY27 was ₹ 183 Cr (4.3% of Revenue), increased by 34% Y/Y due to development efforts toward building Advanced Biologics infrastructure (Gene Therapy/Antibody Drug Conjugates)  Total R&D investments for Q2 was ₹ 65 Cr (2.9% of Revenue)  Laurus Labs entered into definitive agreement to acquire 60% stake in Canada based Galenvs Science, specialized in Oligonucleotide and precision magnetic nanoparticles. The investment strengthens technology platform to deliver a seamless, end-to-end oligonucleotide offering by combining Galenvs early-stage development, conjugation, advanced purification, and fill-finish with Laurus Lab’s large-scale manufacturing expertise in complex chemistry, fermentation, peptides, analytical science, and sterile drug formulation. The tran [Showing first 8,000 characters — download PDF for full document]